# AstraZeneca’s Lynparza approved in China for prostate cancer

- Link: https://www.directorstalkinterviews.com/astrazenecas-lynparza-approved-in-china-for-prostate-cancer/4121003924
- Published: 2021-06-24T07:41:58+01:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
and MSD’s _Lynparza_ (olaparib) has been granted conditional approval in China to
treat adult patients with germline or somatic BRCA-mutated metastatic castration-
resistant prostate cancer (mCRPC) who have progressed following treatment that included
a new hormonal agent (abiraterone, enzalutamide).

In China, prostate cancer is the sixth most prevalent cancer in men, with approximately
115,000 new patients diagnosed each year and about 7% have germline BRCA mutations.
^(1,2) Prostate cancer patients with these mutations are more likely to have poorer
outcomes than those without the mutations.^(3) Around 70% of prostate cancer patients
in China have advanced disease at the time of diagnosis, and for those with mCRPC,
the median survival is less than two years.^(4,5)

The approval by China’s National Medical Products Administration was based on a 
subgroup analysis of the PROfound Phase III trial, which showed that _Lynparza_ 
demonstrated a substantial improvement in radiographic progression-free survival(
rPFS) and overall survival (OS) versus abiraterone or enzalutamide in men with BRCA1/
2 mutations. Continued approval is contingent upon verification and description 
of clinical benefit in a planned bridging trial with Chinese patients.

> **Dave Fredrickson, Executive Vice President, Oncology Business Unit, said**: “
> This approval begins a new era of precision medicine for patients in China with
> advanced prostate cancer who have historically had a poor prognosis and few treatment
> options. _Lynparza_ more than tripled radiographic progression-free survival in
> the PROfound trial and is the only PARP inhibitor to show an overall survival 
> benefit compared to treatment with new hormonal agents for men with BRCA-mutated
> metastatic castration-resistant prostate cancer.”

> **Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief
> Medical Officer, MSD Research Laboratories, said**: “The approval underscores 
> the critical importance of BRCA testing in men with prostate cancer. We are proud
> to provide a new personalised treatment option for men with this devastating disease
> in China, and we will continue to collaborate with the Chinese government and 
> healthcare organisations to bring _Lynparza_ to patients who need it.”

The subgroup analysis from the PROfound Phase III trial showed _Lynparza_ reduced
the risk of disease progression or death by 78% (based on a hazard ratio [HR] of
0.22, 95% confidence interval [CI] 0.15-0.32; nominal p<0.0001) and improved rPFS
to a median of 9.8 months versus 3.0 with abiraterone or enzalutamide in men with
mCRPC with BRCA1/2 mutations. In addition, _Lynparza_ reduced the risk of death 
by 37% (HR of 0.63, 95% CI 0.42-0.95) with median OS of 20.1 months versus 14.4 
with abiraterone or enzalutamide.

The primary results and OS results from the PROfound Phase III trial were published
in _The New England Journal of Medicine_.

_Lynparza_ is approved in the US to treat men with homologous recombination repair
gene-mutated (HRRm) mCRPC and in the EU, Japan and several other countries for BRCA-
mutated mCRPC patients based on the PROfound Phase III trial. In addition, regulatory
reviews are ongoing in other countries around the world.

AstraZeneca and MSD are testing _Lynparza_ in additional trials in metastatic prostate
cancer, including the ongoing PROpel Phase III trial of _Lynparza_ as a 1st-line
treatment for patients with mCRPC in combination with abiraterone versus abiraterone
alone. Results are anticipated in the second half of 2021.

Share on:
